Associations - Tyvyt (sintilimab)

No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
No biomarker	Lung Non-Small Cell Squamous Cancer	No biomarker	Lung Non-Small Cell Squamous Cancer	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
No biomarker	Esophageal Squamous Cell Carcinoma	No biomarker	Esophageal Squamous Cell Carcinoma	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
No biomarker	Gastric Cancer	No biomarker	Gastric Cancer	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
No biomarker	Gastroesophageal Junction Adenocarcinoma	No biomarker	Gastroesophageal Junction Adenocarcinoma	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1	sintilimab Sensitive: A1 - Approval sintilimab Sensitive : A1
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B
MHC-II overexpression + PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer	MHC-II overexpression + PD-L1 negative	Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B
MHC-II overexpression + PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer	MHC-II overexpression + PD-L1 underexpression	Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B	sintilimab Sensitive: B - Late Trials sintilimab Sensitive : B
EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	EGFR mutation	Lung Non-Squamous Non-Small Cell Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: B - Late Trials sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : B
PD-L1 expression	Small Cell Lung Cancer	PD-L1 expression	Small Cell Lung Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
ALK mutation	Non Small Cell Lung Cancer	ALK mutation	Non Small Cell Lung Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
TMB-H	Gastric Cancer	TMB-H	Gastric Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
MSI-H/dMMR	Rectal Cancer	MSI-H/dMMR	Rectal Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
TMB-H	Solid Tumor	TMB-H	Solid Tumor	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
EGFR L861Q	Non Small Cell Lung Cancer	EGFR L861Q	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	EGFR wild-type	Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2	sintilimab Sensitive: C2 – Inclusion Criteria sintilimab Sensitive : C2
CHD8 mutation	Hodgkin Lymphoma	CHD8 mutation	Hodgkin Lymphoma	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3
CELF2 mutation	Hodgkin Lymphoma	CELF2 mutation	Hodgkin Lymphoma	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3
TNFRSF14 mutation	Hodgkin Lymphoma	TNFRSF14 mutation	Hodgkin Lymphoma	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3	sintilimab Resistant: C3 – Early Trials sintilimab Resistant : C3
ALK positive	Non Small Cell Lung Cancer	ALK positive	Non Small Cell Lung Cancer	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
EGFR expression	Non Small Cell Lung Cancer	EGFR expression	Non Small Cell Lung Cancer	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
PD-L1 expression	Cervical Cancer	PD-L1 expression	Cervical Cancer	anlotinib + sintilimab Sensitive: C3 – Early Trials anlotinib + sintilimab Sensitive : C3	anlotinib + sintilimab Sensitive: C3 – Early Trials anlotinib + sintilimab Sensitive : C3
FANCA mutation	Colorectal Cancer	FANCA mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
NOTCH1 mutation	Colorectal Cancer	NOTCH1 mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
STAG2 mutation	Colorectal Cancer	STAG2 mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3
AMER1 mutation	Colorectal Cancer	AMER1 mutation	Colorectal Cancer	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3	sintilimab + fruquintinib Resistant: C3 – Early Trials sintilimab + fruquintinib Resistant : C3

Tyvyt (sintilimab)

Associations
(89)

Associations
(89)

Tyvyt (sintilimab)

Associations(89)

Associations(89)

Associations
(89)

Associations
(89)